Soligenix, Inc. Common Stock

SNGXNASDAQ • USD
ThemeBiotech - Drug Development›Rare Disease Therapeutics
0.39 USD
↗ 0.00 (0.00%)AT CLOSE (11:59 AM EDT)
0.39
↘ 0.00 (0.28%)
POST MARKET (AS OF 07:52 PM EDT)
Post Market
AS OF 07:52 PM EDT
0.39
↘ 0.00 (0.28%)
🔴Market: CLOSED
Open?$0.39
High?$0.41
Low?$0.38
Prev. Close?$0.39
Volume?946.3K
Avg. Volume?1.4M
VWAP?$0.40
Rel. Volume?0.67x
Bid / Ask
Bid?$0.39 × 1.0K
Ask?$0.39 × 15.2K
Spread?$0.00
Midpoint?$0.39
Valuation & Ratios
Market Cap?5.8M
Shares Out?14.8M
Float?9.8M
Float %?96.9%
P/E Ratio?N/A
P/B Ratio?1.87
EPS?-$0.74
Dividend?0.00%
Ex-Dividend?N/A

Soligenix, Inc. Common Stock (SNGX) is currently trading at $0.40. The stock presents a bearish profile across the board: technical indicators signal "Sell" and our fundamental models agree with a "Sell" rating. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of May 22, 2026.

News
Profile
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
Themes
Biotech - Drug Development›Rare Disease TherapeuticsBiotech - Drug Development›Infectious Disease & VaccinesDefense & National Security›Defense Supply Chain & Components
Employees
14
Market Cap
5.8M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.soligenix.com
Listed
1994-04-05
Address
29 EMMONS DRIVE
PRINCETON, NJ 08540
Phone: 609-538-8200
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
77
Short Sent.?
63
Piotroski F-Score?0/9Weak
Altman Z-Score?-54.29Distress
Confidence?41%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?10.46%High
Short Interest?1.0M
Days to Cover?1.0
Free Float9.8M
Avg Daily Volume2.1M
Settlement Date2026-04-30
Financial Health
Current Ratio?1.81Adequate
Quick Ratio?1.81Adequate
Cash Ratio?1.67Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
78
1.87CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
Peers
100
S&P
97
0.0CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-354.5%WEAK▾
ROA?
S&P
3
-158.2%WEAK▾
Cash Flow & Enterprise
FCF?$-10783147
Enterprise Value?$-248002
Fundamentals ratios updated end of day
MarketsMoversWatchlist